Shots:

• The P-III KEYNOTE-426 Study involves assessing of Keytruda (pembrolizumab- 200mg- IV- q3w) + Inlyta (axitinib- 5mg- PO- bid) vs sunitinib (50 mg- PO- qd@4w) monothx in 861 patients with 1L Advanced RCC
• P-III KEYNOTE-426 results: Reduction in risk of death 47%- 31% reduction in the risk of progression of disease- ORR (59.3% vs 35.7%)- CR (5.8% vs 1.9%)- PR (53.5% vs 33.8%)- survival rate @12/18 mos. (89.9%- 82.3% vs 78.3%- 72.1%)- mPFS (15.1 vs 11.1 mos.)- TRAEs (62.9% vs 58.1%)- Presented at ASCO GU 2019
• Keytruda (pembrolizumab) 100mg IV is a mAb- used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes. The US FDA has granted PR to its sBLA for 1L advance RCC with its PDUFA date 20 Jun-2019

Ref: Merck | Image: Merck